marked.bio

WEE1 inhibitor · small molecule

adavosertib

5 active trials across 6 of our biomarkers, targeting WEE1. Not approved for any biomarker on marked.bio yet.

Also known as AZD1775, MK-1775.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRCA1/2 mutation 3 5 Phase 2
FGFR2 fusion or rearrangement 1 1 Phase 1
FGFR3 alteration (mutation or fusion) 1 1 Phase 1
MSI-H / dMMR 1 1 Phase 2
BRAF V600E 0 1 –
FLT3 mutation (ITD/TKD) 0 1 –

Sponsors

Industry sponsors leading active biomarker-selected trials of adavosertib.

  1. AstraZeneca 1

Trials

5 of 9 trials shown

  1. Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2018Primary completion 2026-12 NCT03579316

    adavosertibolaparib FDA EUceralasertib

    Are germline or somatic BRCA mutant or HRD positive by a licensed test prior to enrollment.

    BRCA1/2 mutationRecurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma

  2. Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2017Primary completion 2020-05 NCT04439227

    adavosertib

    Patients must have mutation in the BRCA1 or BRCA2 gene in the tumor, or another aberration, as determined via the MATCH Master Pr…

    BRCA1/2 mutationAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma

  3. Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2015Primary completion 2027-12 NCT02465060

    adavosertibafatinibbinimetinibcapivasertibcopanlisibcrizotinibdabrafenibDasatinibdefactiniberdafitinibfexagratinibipatasertib

    …candidate for Z1M based on local Clinical Laboratory Improvement Act (CLIA) assessment of mismatch repair deficiency (MMRd) by immunohistochemistry (IHC) or microsatellite instability (MSI) status by polyme…

    MSI-H / dMMRAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma

  4. Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

    Active, not recruiting Phase 1 National Cancer Institute (NCI) Started 2020Primary completion 2023-02 NCT04197713

    adavosertibolaparib FDA EU

    Germline or somatic mutations in BRCA1 or BRCA2

    BRCA1/2 mutationAdvanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm

  5. Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

    Active, not recruiting Phase 1 AstraZeneca Started 2016Primary completion 2020-03 NCT02546661

    fexagratinibdurvalumabolaparibadavosertibVistusertibAZD9150selumetinib

    Confirmation of FGFR3 mutation or FGFR fusion

    FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementMuscle Invasive Bladder Cancer